Back to Search Start Over

A novel nerolidol-rich essential oil from Piper claussenianum modulates Candida albicans biofilm

Authors :
José Alexandre Da Rocha Curvelo
Maristela Barbosa Portela
R.M.A. Soares
Maria Auxiliadora Coelho Kaplan
Maria Teresa Villela Romanos
Anna Léa Silva Barreto
André M. Marques
Source :
Journal of Medical Microbiology. 63:697-702
Publication Year :
2014
Publisher :
Microbiology Society, 2014.

Abstract

Candidiasis is a major opportunistic fungal infection in humans, and its incidence has increased steadily over the last two decades. Candida albicans, the main species of the genus, has a large arsenal of virulence attributes that contribute to successful infections, such as dimorphism and biofilm formation. The adverse effects of eukaryotic antimicrobial therapies associated with an increase in resistance to the compounds presently available have boosted efforts to improve the therapeutic arsenal against candidiasis with a newer and cheaper range of drugs. In this study, a novel nerolidol-rich essential oil (EO) derived from Piper claussenianum (Miq.) C. DC., Piperaceae, was tested on the growth, transition (yeast to hyphae), formation and stability of biofilms produced by C. albicans. Both inflorescence and leaf EOs were evaluated and revealed MIC values ranging from 0.04 to 0.1 % and 0.2 to 1.26 %, respectively. Furthermore, leaf EO managed to downregulate the yeast-to-hyphae transition by 81 %, as well as reducing biofilm formation by about 30 and 50 % after incubation for 24 and 48 h, respectively. The EO was also able to reduce the viability of pre-formed biofilm by 63.9 %. Finally, the association between the leaf EO and fluconazole was evaluated and revealed an interesting synergistic effect. Taken together, these results demonstrate that this novel compound could be a promising agent and could reinforce the arsenal of therapeutic alternatives for the treatment of candidiasis. Furthermore, it may represent a novel and natural source of nerolidol, which could be of interest pharmaceutically.

Details

ISSN :
14735644 and 00222615
Volume :
63
Database :
OpenAIRE
Journal :
Journal of Medical Microbiology
Accession number :
edsair.doi.dedup.....0919cd2a891d7b0559d791662c75ad0c
Full Text :
https://doi.org/10.1099/jmm.0.063834-0